Abstract
A randomized, two-treatment and two-way crossover study on twelve healthy Indian male subjects was conducted to assess the bioequivalence of two tablet formulations containing 20 mg of rimonabant (CAS 158681-13-1). Both of the formulations were administered orally as a single dose with a 45-day washout period between two dosing sessions. The content of rimonabant in plasma was determined by a validated HPLC method with UV detection. The formulations were compared using the parameters area under the plasma concentration-time curve (AUC0−t), area under the plasma concentration-time curve from zero to infinity (AUC0−∞), peak plasma concentration (Cmax), and time to reach peak plasma concentration (tmax). The results of this investigation indicated that there were no statistically significant differences between the logarithmically transformed AUC0−∞ and Cmax values of the two preparations. The 90% confidence interval for the ratio of the logarithmically transformed AUC0−t, AUC0−∞ and Cmax were within the bioequivalence limit of 0.8-1.25 and the relative bioavailability of the test formulation was 96.62% of that of the reference formulation. Thus, these findings clearly indicate that the two formulations are bioequivalent in terms of rate and extent of drug absorption.
Key words
Anti-obesity drug - Bioequivalence - CAS 158681-13-1 - HPLC - Pharmacokinetics - Rimonabant
